Delivers real-time biopharma news and signals — powered by AI, curated for professionals.
In a significant move for the gastrointestinal robotics sector, Swan EndoSurgical, a startup formed by Olympus and Revival Healthcare Capital, has named Erik Todd as its new CEO. Todd, a former Stryker executive with 25 years of experience, brings a wealth of expertise in medical robotics to the fledgling company.
Laboratoires Théa has entered into a significant agreement with Iolyx Therapeutics, potentially worth up to $280 million, to acquire the rights to ILYX-002, a phase 3-ready drug for moderate to severe dry eye disease (DED) associated with systemic autoimmune or inflammatory conditions.
Muvon Therapeutics has announced encouraging phase 2 trial results for its novel cell therapy approach to treating stress urinary incontinence (SUI), potentially offering an alternative to synthetic implants. The small-scale study demonstrated significant reductions in incontinence episodes and urine loss, marking a notable advancement in regenerative medicine for urological conditions.
In recent years, the pharmaceutical industry has witnessed a significant shift in venture capital funding for women-founded biopharma companies. Despite the challenges posed by the post-pandemic environment, these companies have continued to attract substantial investments, contributing to the sector's innovation and growth.
Novo Nordisk and Eli Lilly's recent pricing agreements for their GLP-1 obesity treatments have set the stage for potential new entrants in the cardiometabolic space, according to a 2026 preview report from PitchBook. The deals, part of the TrumpRx initiative, are expected to expand the addressable market and streamline the regulatory pathway for future competitors.
Richard Pazdur, the recently appointed director of the FDA's Center for Drug Evaluation and Research (CDER), has filed paperwork to retire at the end of December, just weeks after accepting the role. This sudden development adds to the ongoing leadership turmoil at the agency and raises concerns about regulatory stability in the pharmaceutical industry.
Imvax, a Philadelphia-based biotech company, is moving forward with plans to approach the FDA regarding its investigational glioblastoma immunotherapy, IGV-001, despite missing the primary endpoint in a recent Phase IIb trial. The company's decision highlights the potential impact of the treatment on overall survival rates and underscores the urgent need for new therapies in this challenging area of oncology.
Roche's recent announcement of a successful Phase I/II trial for its antibody trontinemab has signaled a potential renaissance in Alzheimer's disease treatment, marking the Swiss pharmaceutical giant's return to the forefront of neurodegenerative research. This development comes years after the controversial approval and subsequent withdrawal of Biogen's Aduhelm, which had initially sent shockwaves through the industry.
Roche, the Swiss pharmaceutical giant, has made a significant comeback in the Alzheimer's disease space with its next-generation antibody, trontinemab. The company presented promising results from its ongoing Phase I/II Brainshuttle AD study at the 2025 Clinical Trials on Alzheimer's Disease (CTAD) meeting, showcasing the drug's potential in clearing amyloid plaques and possibly affecting tau protein accumulation in the brain.
Boston Scientific has secured CE Mark approval for its Farapoint focal catheter, the latest addition to its pulsed field ablation (PFA) portfolio. This development marks a significant expansion of the company's Farapulse platform for treating irregular heart rhythms, now including the treatment of right atrial flutter.
Cleveland Diagnostics has received Food and Drug Administration (FDA) approval for its innovative prostate cancer test, IsoPSA, marking a significant advancement in prostate cancer diagnostics. The test, designed for men aged 50 and older with elevated prostate-specific antigen (PSA) levels, aims to improve risk assessment and reduce unnecessary biopsies.
Janux Therapeutics has released new data for its investigational T-cell engager JANX007, currently in phase 1a/1b trials for advanced castration-resistant prostate cancer. The update, while showing promise, has led to a significant drop in the company's stock price.
